MolDX: Inivata™, InVisionFirst®, Liquid Biopsy for Patients with Lung Cancer

InVisionFirst (plasma-based CGP) is covered only for patients with advanced (Stage IIIB/IV) non-small cell lung cancer when tissue-based comprehensive genomic profiling is infeasible, specifically at diagnosis if EGFR/ALK/ROS1/BRAF test results are unavailable, at progression after chemo/immunotherapy if those tests haven't been done, or for progression on EGFR TKIs. Negative or insufficient plasma ctDNA results do not exclude genomic alterations and should prompt consideration of tissue-based genotyping. Documentation must show advanced stage, infeasibility of tissue testing (QNS or contraindication), unavailable prior biomarker results when applicable, and treatment/progression history.

"InVisionFirst (plasma-based CGP) is covered for patients with advanced (Stage IIIB or IV) non-small cell lung cancer at diagnosis when results for EGFR SNVs/indels, ALK and ROS1 rearrangements, and..."